John Carreyrou's investigation into Theranos exposes the greatest corporate fraud in a generation. For investors, it is the definitive case study in due diligence failure — showing how celebrity boards, FOMO investing, and lack of technical scrutiny allowed a $9 billion valuation built on technology that never worked. Essential reading for avoiding the next Theranos.
Listen time: 15 minutes. Smallfolk Academy's AI-narrated summary distills the book's core ideas into a focused audio session.
Key Concepts from Bad Blood
Due Diligence Red Flags: When Elizabeth Holmes pitched Theranos to investors, she promised revolutionary blood-testing technology that could run hundreds of tests from a single drop of blood. But there was one catch – she refused to let anyone actually see how the technology worked. This scenario perfectly illustrates critical due diligence red flags that every investor must learn to recognize: excessive secrecy, blocked verification attempts, and barriers to independent assessment.
Due diligence red flags are warning signals that suggest a company may be hiding fundamental problems or even engaging in fraud. While some secrecy is normal in competitive industries, certain behaviors should immediately raise concerns. These include refusing technical audits, limiting access to key performance data, over-relying on non-disclosure agreements, avoiding direct answers to technical questions, and restricting investor access to facilities or key personnel.
The Theranos case shows how these red flags play out in practice. When Walgreens wanted to partner with Theranos, they were denied the chance to observe the actual testing process. Investors like the DeVos family invested millions without ever seeing a demonstration of the core technology. Even board members were kept in the dark about technical details. Meanwhile, Theranos used aggressive NDAs and legal threats to silence anyone who tried to investigate or speak out about the company's claims.
Smart investors know that legitimate companies with groundbreaking technology welcome qualified scrutiny because it validates their achievements and builds confidence. When a company claims to have revolutionary technology but won't prove it works, that's not protecting trade secrets – that's a massive red flag. Real innovation can typically be demonstrated safely without revealing proprietary details.
The key lesson from Theranos is simple: extraordinary claims require extraordinary evidence. When a company blocks your attempts to verify their core claims, walk away. No investment opportunity is worth ignoring fundamental due diligence red flags, no matter how promising the pitch sounds or how impressive the team appears on paper. (Chapter 8)
The Halo Effect of Celebrity Boards: When evaluating investment opportunities, many investors fall prey to the "halo effect" of celebrity board members – the tendency to assume that prestigious names automatically validate a company's credibility and prospects. Theranos masterfully exploited this psychological bias by assembling a board that read like a who's who of American politics and military leadership, including former Secretary of State Henry Kissinger, former Secretary of State George Shultz, and decorated generals. While these individuals commanded immense respect in their respective fields, none possessed the scientific or healthcare expertise necessary to scrutinize Theranos's bold claims about revolutionary blood testing technology.
This mismatch between board prestige and domain expertise created a dangerous blind spot that should serve as a cautionary tale for all investors. Celebrity board members often lend their names and reputations to companies without conducting the rigorous due diligence that their stature implies to outside observers. In Theranos's case, these distinguished leaders were largely kept in the dark about the company's actual technological capabilities, yet their presence on the board provided an aura of legitimacy that helped attract billions in investment capital.
The practical implications extend far beyond Theranos to countless investment decisions made daily across markets. When evaluating any investment opportunity, savvy investors should look beyond the impressive résumés and ask pointed questions: Do board members have relevant industry experience? Are they asking the right technical questions during board meetings? Have they personally validated the company's core value proposition within their area of expertise?
Smart investors should treat celebrity board members as a potential red flag rather than an automatic green light. A board stacked with prestigious names but lacking domain knowledge often indicates that a company is prioritizing perception over substance. The most effective boards combine respected leadership with deep, relevant expertise – individuals who can challenge management's assumptions, understand industry-specific risks, and provide meaningful strategic guidance rather than just lending their famous names to letterhead and marketing materials. (Chapter 5)
Founder Cult of Personality Risk: The "Founder Cult of Personality Risk" occurs when a charismatic entrepreneur becomes so central to their company's story that investors focus more on the founder's personal brand than on actual business fundamentals. Elizabeth Holmes masterfully crafted this phenomenon at Theranos, adopting Steve Jobs's signature black turtlenecks, delivering captivating TED talks, and cultivating an image as a visionary genius who would revolutionize healthcare. Her media presence was so compelling that it created what Silicon Valley calls a "reality distortion field" – a bubble where excitement about the founder's persona overshadows critical analysis of the company's actual performance.
This risk matters enormously for investors because charismatic founders can obscure red flags that should trigger deeper scrutiny. When Holmes graced magazine covers and commanded standing ovations, investors like Walgreens, Safeway, and prominent venture capitalists poured in over $900 million without ever seeing comprehensive data about Theranos's technology. The founder's star power became a substitute for due diligence, leading investors to make decisions based on narrative rather than numbers.
The warning signs are often hiding in plain sight. At Theranos, the company operated in extreme secrecy, had an unusually small board dominated by political figures rather than medical experts, and consistently deflected technical questions with vague promises about proprietary breakthroughs. Holmes's carefully choreographed public appearances featured inspiring speeches about changing the world, but notably lacked detailed explanations of how the technology actually worked or concrete evidence of its effectiveness.
Smart investors can protect themselves by maintaining what Warren Buffett calls "rational skepticism." When evaluating any investment opportunity, ask hard questions: Can the company's claims be independently verified? Does the leadership team include relevant technical experts? Are financial projections supported by transparent data? Most importantly, remember that great companies are built on great products and sustainable business models, not just great storytellers.
The key takeaway is simple but powerful: invest in businesses, not personalities. While visionary leadership certainly matters, it should complement solid fundamentals, not replace them. When media buzz about a founder starts drowning out discussion of actual business metrics, that's your cue to dig deeper – or walk away entirely. (Chapter 3)
Vaporware and the 'Fake It Till You Make It' Trap: The term "vaporware" originated in the tech industry to describe products that are announced and hyped but never actually delivered or exist only as non-functional prototypes. In the investment world, this concept takes on dangerous new meaning when companies like Theranos deliberately misrepresent their capabilities to attract funding. While ambitious startups often stretch the truth about their timeline or potential, there's a crucial line between optimistic projections and outright fraud that every investor must learn to identify.
The Theranos scandal perfectly illustrates how vaporware can devastate investors who fail to conduct proper due diligence. Elizabeth Holmes claimed her company could run hundreds of tests from a single drop of blood using revolutionary technology, but investigations revealed that most tests were actually performed on traditional machines using diluted samples. The company's signature "Edison" devices were essentially elaborate props designed to impress investors and partners during demonstrations.
For investors, distinguishing between legitimate early-stage companies and vaporware schemes requires asking the right questions and demanding verifiable proof. Red flags include excessive secrecy around technology (Theranos claimed trade secrets prevented demonstrations), lack of peer-reviewed publications, missing key technical personnel, and reluctance to provide references from actual users. Legitimate companies may have incomplete products, but they're typically transparent about their current limitations and development roadmap.
The financial consequences of falling for vaporware can be catastrophic – Theranos investors lost over $900 million when the company collapsed. Beyond monetary losses, these scandals damage investor confidence in genuinely innovative companies that may be working on breakthrough technologies. This creates a ripple effect that can harm legitimate startups seeking funding for real innovations.
The key lesson for investors is to maintain healthy skepticism while staying open to genuine innovation. Always demand independent verification of claims, insist on meeting technical teams, and look for third-party validation through partnerships or pilot programs. Remember that extraordinary claims require extraordinary evidence – if a company claims to have solved problems that have stumped entire industries, they should have compelling proof beyond slick presentations and charismatic founders. (Chapter 10)
Whistleblower Signals as Investment Intelligence: When employees within a company start raising serious concerns about business practices, product quality, or financial irregularities, smart investors should pay attention—especially when management responds with aggressive legal tactics rather than transparent investigation. Whistleblower signals represent one of the most valuable but underutilized sources of investment intelligence, often providing early warning signs of corporate disasters that can wipe out billions in shareholder value.
The Theranos case perfectly illustrates this principle in action. Multiple employees, including lab technicians and engineers, repeatedly raised alarms about the company's blood-testing technology not working as advertised. Instead of addressing these concerns transparently, Elizabeth Holmes and her team responded with non-disclosure agreements, legal threats, and a culture of fear designed to silence internal critics. This pattern of aggressive suppression should have been a massive red flag for investors, as it often indicates management knows about fundamental problems but chooses to hide them rather than fix them.
From an investment perspective, companies that resort to legal intimidation tactics against their own employees are essentially waving a warning banner. Healthy companies welcome internal feedback and address legitimate concerns through proper channels. When management's first instinct is to lawyer up and silence critics rather than investigate claims, it suggests they're more concerned with protecting a false narrative than building sustainable business value. This behavior pattern frequently precedes major corporate scandals and stock collapses.
Savvy investors can use this intelligence by monitoring news reports about employee lawsuits, SEC whistleblower filings, and unusual employee turnover patterns, particularly in critical departments like quality control, finance, or regulatory compliance. Pay special attention when companies with already questionable financials or unproven business models face internal criticism—this combination often signals an impending collapse.
The key takeaway is that whistleblowers are often your best early warning system for investment disasters. When employees risk their careers to expose problems, and companies respond with legal warfare instead of genuine investigation, it's time to seriously reconsider your investment thesis. Remember: companies that have nothing to hide don't typically spend enormous resources trying to silence their own people. (Chapter 14)
About the Author
John Carreyrou is a two-time Pulitzer Prize-winning investigative reporter who spent over 20 years at The Wall Street Journal. His reporting on Theranos, which began in 2015, directly led to the company's collapse and Elizabeth Holmes's criminal conviction. Bad Blood won the Financial Times and McKinsey Business Book of the Year Award in 2018 and has been adapted into a podcast and an upcoming film. Carreyrou is considered one of the most impactful business journalists of his generation.
Frequently Asked Questions
What is the single biggest investor lesson from Bad Blood?
Never invest in what you cannot independently verify. Theranos raised billions because investors trusted the founder's narrative instead of demanding technical proof. Always insist on verifiable evidence of a company's core claims.
How did Theranos fool so many sophisticated investors?
A combination of FOMO, celebrity board members, extreme secrecy disguised as trade secret protection, and Holmes's compelling storytelling. The book shows how social proof and urgency can override rational analysis.
What red flags should investors watch for after reading this book?
Companies that refuse independent audits, threaten employees with legal action for speaking up, have boards lacking industry expertise, and show a gap between public claims and verifiable results.
Is Bad Blood relevant beyond healthcare investing?
Absolutely. The fraud patterns — inflated claims, suppressed dissent, celebrity endorsements substituting for proof — appear across industries. The book is relevant to any investor evaluating pre-revenue or early-stage companies.
How does this book compare to the Theranos documentary?
The book provides far more detail on the financial mechanics and investor failures. The documentary focuses more on Holmes personally. For investors, the book is significantly more useful.
What happened to Theranos investors' money?
Investors lost over $600 million. Walgreens and Safeway lost hundreds of millions more in partnership deals. The book traces exactly how each party was deceived, providing a roadmap of what went wrong at every level.
Could a Theranos-level fraud happen again?
Yes. The book reveals systemic weaknesses in private market investing — limited disclosure requirements, reliance on founder reputation, and herd behavior among VCs — that still exist today.
What role did media play in the Theranos fraud?
Positive media coverage from Fortune, Forbes, and others amplified Holmes's credibility without technical verification. Investors learn to be skeptical of media-driven investment narratives.
How does the book portray Elizabeth Holmes?
As a charismatic but deceptive founder who prioritized personal fame over patient safety. The portrayal teaches investors that founder charisma can mask fundamental business problems.
How long is Bad Blood and is it hard to read?
At roughly 340 pages, it reads like a thriller. Carreyrou's investigative storytelling makes complex medical technology and corporate fraud accessible to any reader.